Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.

NCT05753826 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER_GOV

Sponsor class

Conditions

Ovarian Neoplasms
Ovarian Diseases

Interventions

DRUG: Adebrelimab
DRUG: Fuzuloparib

Sponsor

Fujian Cancer Hospital